Burhan, A. M. http://orcid.org/0000-0002-9888-008X
Anazodo, U. C.
Marlatt, N. M.
Palaniyappan, L.
Blair, M.
Finger, E.
Article History
Received: 10 January 2021
Accepted: 25 June 2021
First Online: 3 July 2021
Declarations
:
: The patient and their study partner had completed written consent for the PET imaging study as approved the by Human Subjects Research Ethics board at Western University (study #103392).
: Consent obtained from patient and substitute decision maker to publish deidentified details of the case, institutional approved written consent is filed in patient’s medical records at Parkwood Institute-Mental Health Building in London Ontario, Canada.
: None identifiedAMB served on an advisory board with Janssen Pharmaceutical related to es-ketamine for treatment resistant depression and provided consultation to Atheneum consulting firm related to dementia assessment and care.EF has received personal compensation for serving on a PSP scientific advisory board for Biogen, for serving as a section editor for NeuroImage Clinical, and for serving as a course director for the AAN annual meeting. Dr. Finger has received research support paid to her institution (UWO or Lawson) from CIHR, the Weston Foundation, Alzheimer Society of Canada, and the Physicians and Services Incorporated Foundation, the Ministry of Research and Innovation of Ontario, and for site participation in clinical trials sponsored by Alector, Biogen, and TauRx.LP reports personal fees from Janssen Canada, Otsuka Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Janssen Canada, Sunovion and Otsuka Canada outside the submitted work.UCA, NM, and MB have no disclosures.